Literature DB >> 6127382

Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen.

B Nunn, P D Chamberlain.   

Abstract

The effect of nabumetone (BRL 14777) on human platelet reactivity ex vivo was compared with that of naproxen at equitherapeutic doses in the same six subjects. Nabumetone had only a weak and equivocal effect on collagen-induced and second phase aggregation in response to adenosine diphosphate and adrenaline. After nabumetone, platelets fully aggregated in response to sodium arachidonate, though approximately twice as much was needed as on control occasions. Sodium arachidonate was unable to elicit a full aggregation response after naproxen. These results suggest that nabumetone may cause less interference with haemostasis than other non-steroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127382     DOI: 10.1111/j.2042-7158.1982.tb04796.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  A placebo-controlled study of interaction between nabumetone and acenocoumarol.

Authors:  A Pardo; M García-Losa; A Fernández-Pavón; S del Castillo; T Pascual-García; E García-Méndez; R Dal-Ré
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 2.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.

Authors:  H A Friedel; P A Todd
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

4.  Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.

Authors:  R Melarange; C Gentry; M Durie; C O'Connell; P R Blower
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.